News & Events
AIMEDICS secures funding for the commercialisation of its overnight hypoglycaemia monitor
27 / 08 / 2010
KaloBios, Seeking to Apply Antibodies Beyond Cancer, Sets Sight on Killing Deadly Lung Invader
17 / 08 / 2010
ChemGenex and U.S. FDA Agree on Potential Regulatory Pathway for OMAPRO:
13 / 07 / 2010
• Company will submit new NDA in CML patients who have failed multiple TKIs • Investor Teleconference to be held today - Wednesday 14th July 10.30am AEST /Tuesday 13th July 5.30
Viveve-Sponsored Research Accepted for Presentation at Two Prestigious International Conferences
13 / 07 / 2010
Women’s Sexual Health Research on Podium at 2010 Joint ICS/IUGA Meeting
UPTAKE MEDICAL COMPLETES SERIES B FINANCING ROUNDFOR $17.5 MILLION -Seattle, Wash. and Irvine, Calif., USA
07 / 07 / 2010
CoDa Therapeutics Achieves Positive Phase 2 Efficacy of NEXAGON® in Chronic Venous Leg Ulcers
29 / 06 / 2010
ASX Announcement First Minimally Invasive C-Pulse Procedure Performed at University of Louisville Sydney, Australia
15 / 06 / 2010
CoDa Therapeutics Achieves Positive Phase 2 Efficacy of NEXAGON® in Chronic Venous Leg Ulcers
25 / 05 / 2010
CoDa Therapeutics Achieves Positive Phase 2 Efficacy of NEXAGON® in Chronic Venous Leg Ulcers - 69% Reduction in Venous Leg Ulcer Size in High-Dose Arm at 4 Weeks - 31% of Wounds Completely Healed in High-Dose Arm at 4 Weeks
CHEMGENEX TO HOST INVESTOR BRIEFING MELBOURNE, Australia, and MENLO PARK, California U.S.A. (4 May 2010)
04 / 05 / 2010
CHEMGENEX RECEIVES A COMPLETE RESPONSE LETTER FROM THE FDA FOR OMAPROTM MELBOURNE, Australia, and MENLO PARK, California U.S.A. (12th April 2010)
12 / 04 / 2010
ChemGenex Pharmaceuticals announces that the U.S. Food and Drug Administration’s (FDA) Office of Oncology Drug Products has issued a complete response letter regarding the new drug application (NDA) for OMAPRO™ (omacetaxine mepesuccinate) for the treatment of adults with chronic myeloid leukemia (CML) who have failed prior therapy with imatinib and have the Bcr-Abl T315I mutation. The complete response letter does not contain a request for a new study, nor is there a request for enrollment of additional patients into the pivotal study on OMAPRO.